Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia

Current Oncology Reports

Volumn 6, Issue 5, 2004, Pages 348-354

  Zent, Clive S ^a   Kay, Neil E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN KINASE ZAP 70;

CANCER DIAGNOSIS; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; HUMAN; OUTCOMES RESEARCH; PATIENT CARE; PREDICTION; PROGNOSIS; REVIEW;

EID: 4544260366     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-004-0060-z     Document Type: Review

References (55)

1. Zent CS, Kyasa MJ, Evans R, Schichman SA: Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer 2001, 92:1325-1330.
2. Muller-Hermelink HK, Catovsky D, Montserrat E, Harris NL: Chronic lymphocytic leukemia/small lymphocytic lymphoma. In Tumours of Haematopoietic and Lymphoid Tissues. Edited by Jaffe E, Harris N, Stein H, Vardiman J. Lyon, France: IARC Press; 2001:127-130.
3. Dighiero G, Binet J-L: When and how to treat chronic lymphocytic leukemia. N Engl J Med 2000, 343:1799-1801.
4. Guarini A, Gaidano G, Mauro FR, et al.: Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. Blood 2003, 102:1035-1041.
5. Byrd JC, Murphy T, Howard RS, et al.: Rituximab using a thrice weekly dosing schedule in B-cell lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001, 19:2153-2164.
6. Cheson BD, Bennett JM, Grever M, et al.: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996, 87:4990-4997.
7. Swerdlow SH, Nathwani BN, Berger F, et al.: Mantle cell lymphoma. In Tumours of Haematopoietic and Lymphoid Tissues. Edited by Jaffe E, Harris N, Stein H, Vardiman J. Lyon, France: IARC Press; 2001:168-170.
8. Harris N, Jaffe E, Stein H, et al.: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392.
9. Chiorazzi N, Ferrarini M: B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 2003, 21:841-894.
10. Caligaris-Cappio F: B-Chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood 1996, 87:2 615-2620.
11. Coffman RL, Cohn M: The class of surface immunoglobulin on virgin and memory B lymphocytes. J Immunol 1977, 118:1806-1815.
12. Hashimoto S, Dono M, Wakai M, et al.: Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells. J Exp Med 1995, 181:1507-1517.
13. Damle RN, Ghiotto F, Valetto A, et al.: B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002, 99:4087-4093.
14. Klein U, Tu Y, Stolovitzky G, et al.: Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001, 194:1625-1638.
15. Rosenwald A, Alizadeh AA, Widhopf G, et al.: Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001, 194:1639-1647.
16. Dighiero G, Maloum K, Desablens B, et al.: Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 1998, 338:1506-1514.
17. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst 1999, 91:861-868.
18. Rai KR, Sawitsky A, Cronkite EP, et al.: Clinical staging of chronic lymphocytic leukemia. Blood 1975, 46:219-234.
19. Binet JL, Auquier A, Dighiero G, et al.: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981, 48:198-205.
20. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C: Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986, 62:567-575.
21. Montserrat E, Rozman C: Bone marrow biopsy in chronic lymphocytic leukemia: a review of its prognostic importance. Blood Cells 1987, 12:315-326.
22. Morrison VA: Infections in patients with chronic lymphocytic leukemia. In Chronic Lymphocytic Leukemias, edn 2. Edited by Cheson BD. New York: Marcel Dekker, 2001:505-523.
23. Weeks JC, Tierney MR, Weinstein MC: Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991, 325:81-86.
24. Bartik MM, Welker D, Kay NE: Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin Oncol 1998, 25:27-33.
25. Kyasa MJ, Parrish RS, Schichman SA, Zent CS: Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 2003, 74:1-8.
26. Diehl L, Ketchum L: Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998, 2180-97.
27. Kyasa MJ, Hazlett L, Parrish RS, et al.: Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death. Leuk Lymphoma 2004, 45:507-513.
28. Giles F, O'Brien S, Keating M: Chronic lymphocytic leukemia in (Richter's) transformation. Semin Oncol 1998, 25:117-125.
29. Hisada M, Biggar R, Greene M, et al.: Solid tumors after chronic lymphocytic leukemia. Blood 2001, 98:1979-1981.
30. Shanafelt TD, Geyer SM, Kay NE: Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004, 103:1202-1210.
31. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987-994.
32. Feldmann M: Cell cooperation in the antibody response. In Immunology, edn 5. Edited by Roitt I, Brostoff J, Male D. London: Mosby; 1998:139-155.
33. Damle RN, Wasil T, Fais F, et al.: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
34. Hamblin T, Davis Z, Gardiner A, et al.: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
35. Jelinek DF, Tschumper RC, Geyer SM, et al.: Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001, 115:854-861.
36. Oscier DG, Gardiner AC, Mould SJ, et al.: Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002, 100:1177-1184.
37. Tobin G, Thunberg U, Johnson A, et al.: Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003, 101:4952-4957.
38. Deaglio S, Capobianco A, Bergui L, et al.: CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003, 102:2146-2155.
39. Zent CS, Zhan F, Schichman SA, et al.: The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype. Leuk Res 2003, 27:765-774.
40. Ibrahim S, Keating M, Do KA, et al.: CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001, 98:181-186.
41. Hamblin TJ, Orchard JA, Ibbotson RE, et al.: CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002, 99:1023-1029.
42. Crespo M, Bosch F, Villamor N, et al.: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, 348:1764-1775.
43. Wiestner A, Rosenwald A, Barry TS, et al.: ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003, 101:4944-4951.
44. Chen L, Widhopf G, Huynh L, et al.: Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002, 100:4609-4614.
45. Rassenti LZ, Huynh L, Toy TL, et al.: Zap-70 is a more reliable marker of disease progression risk than immunoglobulin mutation status in chronic lymphocytic leukemia. Blood 2003, 102:34a.
46. Durig J, Nuckel H, Cremer M, et al.: ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003, 17:2426-2434.
47. Orchard JA, Ibbotson RE, Davis Z,et al.: ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004, 363:105-111.
48. Pittner BT, Tschumper RC, Kimlinger TK, et al.: Expression of ZAP-70 in both unmutated and mutated leukemic CLL B cells indicates lack of efficacy as a surrogate marker for immunoglobulin mutational status. Blood 2003, 102:34a-35a.
49. Calin GA, Dumitru CD, Shimizu M, et al.: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 99:15524-15529.
50. Döhner H, Stilgenbauer S, Benner A, et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.
51. Cuneo A, Rigolin GM, Bigoni R, et al.: Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. Leukemia 2004, 18:476-483.
52. Dewald GW, Brockman SR, Paternoster SF, et al.: Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003, 121:287-295.
53. Dohner H, Stilgenbauer S, James MR, et al.: 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997, 89:2516-2522.
54. Lozanski G, Heerema NA, Flinn IW, et al.: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004, 103:3278-3281.
55. Cochran DA, Evans CA, Blinco D, et al.: Proteomic analysis of chronic lymphocytic leukemia subtypes with mutated or unmutated Ig VH cenes. Mol Cell Proteomics 2003, 2:1331-1341.